Hyaluronan inhibits Tlr-4-dependent RANKL expression in human

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Watanabe, Tatsuo ^a   Takahashi, Nobunori ^a   Hirabara, Shinya ^a   Ishiguro, Naoki ^a   Kojima, Toshihisa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; LIPOPOLYSACCHARIDE; OSTEOCLAST DIFFERENTIATION FACTOR; TOLL LIKE RECEPTOR 4; TLR4 PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; SYNOVIAL FIBROBLAST; UPREGULATION; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SYNOVIUM;

ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; CELLS, CULTURED; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; HYALURONIC ACID; RANK LIGAND; SYNOVIAL MEMBRANE; TOLL-LIKE RECEPTOR 4;

EID: 84963723116     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153142     Document Type: Article

References (30)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. The New England journal of medicine. 2011; 365(23):2205-19. Epub 2011/12/14. doi:10.1056/NEJMra1004965 PMID: 22150039.
2. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis and rheumatism. 2013; 65(1):28-38. Epub 2012/11/22. doi:10.1002/art.37711PMID: 23169319; PubMed Central PMCID: PMCPmc3572583.
3. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis and rheumatism. 2006; 54(4):1063-74. doi:10.1002/art.21655 PMID: 16572441.
4. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology. 2009; 48(9):1114-21. doi:10.1093/rheumatology/kep155 PMID: 19589891.
5. Drexler SK, Sacre SM, Foxwell BM. Toll-like receptors: A new target in rheumatoid arthritis? Expert review of clinical immunology. 2006; 2(4):585-99. Epub 2006/07/01. doi:10.1586/1744666x.2.4.585 PMID: 20477615.
6. Brentano F, Kyburz D, Schorr O, Gay R, Gay S. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cellular immunology. 2005; 233(2):90-6. doi:10.1016/j.cellimm.2005.04.018 PMID: 15963480.
7. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature immunology. 2010; 11(5):373-84. doi:10.1038/ni.1863 PMID: 20404851.
8. Kyburz D, Rethage J, Seibl R, Lauener R, Gay RE, Carson DA, et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis and rheumatism. 2003; 48(3):642-50. doi: 10.1002/art.10848 PMID: 12632416.
9. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis and rheumatism. 2005; 52(9):2656-65. Epub 2005/09/06. doi:10.1002/art.21273 PMID: 16142732.
10. Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, et al. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll-like receptor expression in early and longstanding arthritis. Arthritis and rheumatism. 2008; 58(12):3684-92. Epub 2008/11/28. doi:10.1002/art.24140 PMID: 19035519.
11. Jin Z, Li X, Wan Y. Nuclear Receptor Regulation of Osteoclast and Bone Remodeling. Molecular endocrinology. 2014:me20141316. doi:10.1210/me.2014-1316 PMID: 25549044.
12. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis and rheumatism. 1984; 27(9):968-75. Epub 1984/09/01. PMID: 6236824.
13. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochemical and biophysical research communications. 1998; 253(2):395-400. Epub 1999/01/08. doi:10.1006/bbrc.1998.9788PMID: 9878548.
14. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis and rheumatism. 2000; 43(2):250-8. Epub 2000/02/29. doi:10.1002/1529-0131(200002)43:2<250::aid-anr3>3.0.co;2-p PMID: 10693863.
15. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis and rheumatism. 2000; 43(2):259-69. Epub 2000/02/29. doi:10.1002/1529-0131(200002)43:2<259::aid-anr4>3.0.co;2-w PMID: 10693864.
16. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiological reviews. 2011; 91(1):221-64. doi:10.1152/physrev.00052.2009PMID: 21248167; PubMed Central PMCID: PMC3051404.
17. Saito S, Momohara S, Taniguchi A, Yamanaka H. The intra-articular efficacy of hyaluronate injections in the treatment of rheumatoid arthritis. Modern rheumatology/the Japan Rheumatism Association. 2009; 19(6):643-51. Epub 2009/08/04. doi:10.1007/s10165-009-0207-8 PMID: 19649562.
18. Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 Revised Criteria for The Classification Of Rheumatoid Arthritis. Arthritis and rheumatism. 1988; 32(3):315-23.
19. Ohno S, Im HJ, Knudson CB, Knudson W. Hyaluronan oligosaccharide-induced activation of transcription factors in bovine articular chondrocytes. Arthritis and rheumatism. 2005; 52(3):800-9. Epub 2005/03/08. doi:10.1002/art.20937 PMID: 15751080; PubMed Central PMCID: PMCPmc2893143.
20. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology. 2001; 40(6):623-30. Epub 2001/06/27. PMID: 11426018.
21. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis and rheumatism. 2008; 58(5):1299-309. Epub 2008/04/29. doi:10.1002/art.23417 PMID: 18438830.
22. Abdollahi-Roodsaz S, Joosten LA, Helsen MM, Walgreen B, van Lent PL, van den Bersselaar LA, et al. Shift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production. Arthritis and rheumatism. 2008; 58(12):3753-64. doi:10.1002/art.24127 PMID: 19035506.
23. Kim KW, Cho ML, Lee SH, Oh HJ, Kang CM, Ju JH, et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunology letters. 2007; 110(1):54-64. doi:10.1016/j.imlet.2007.03.004 PMID: 17467812.
24. Shimizu M, Yasuda T, Nakagawa T, Yamashita E, Julovi SM, Hiramitsu T, et al. Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines. The Journal of rheumatology. 2003; 30(6):1164-72. Epub 2003/06/05. PMID: 12784385.
25. Hiramitsu T, Yasuda T, Ito H, Shimizu M, Julovi SM, Kakinuma T, et al. Intercellular adhesion molecule- 1 mediates the inhibitory effects of hyaluronan on interleukin-1beta-induced matrix metalloproteinaseproduction in rheumatoid synovial fibroblasts via down-regulation of NF-kappaB and p38. Rheumatology. 2006; 45(7):824-32. doi:10.1093/rheumatology/kel026 PMID: 16449361.
26. Hirabara S, Kojima T, Takahashi N, Hanabayashi M, Ishiguro N. Hyaluronan inhibits TLR-4 dependent cathepsin K and matrix metalloproteinase 1 expression in human fibroblasts. Biochemical and biophysical research communications. 2013; 430(2):519-22. doi:10.1016/j.bbrc.2012.12.003 PMID: 23232115.
27. Ariyoshi W, Okinaga T, Knudson CB, Knudson W, Nishihara T. High molecular weight hyaluronic acid regulates osteoclast formation by inhibiting receptor activator of NF-kappaB ligand through Rho kinase. Osteoarthritis and cartilage/OARS, Osteoarthritis Research Society. 2014; 22(1):111-20. PMID: 24185105.
28. Goto M, Hanyu T, Yoshio T, Matsuno H, Shimizu M, Murata N, et al. Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: A multicenter clinical trial. Clinical and experimental rheumatology. 2001; 19(4):377-83. Epub 2001/08/09. PMID: 11491492.
29. Dahl LB, Dahl IM, Engstrom-Laurent A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Annals of the rheumatic diseases. 1985; 44(12):817-22. Epub 1985/12/01. PMID: 4083937; PubMed Central PMCID: PMCPmc1001790.
30. Julovi SM, Yasuda T, Shimizu M, Hiramitsu T, Nakamura T. Inhibition of interleukin-1beta-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis and rheumatism. 2004; 50(2):516-25. doi:10.1002/art.20004 PMID: 14872494.